Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 21,205 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 2 Interventional Results available

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 26, 2026, 2:52 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Atacicept in IgA Nephropathy

NCT02808429
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, Atacicept 25 mg, Atacicept 75 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 26, 2026, 2:52 AM EDT
Completed No phase listed Observational

Safety Study of GBS Following Menactra Meningococcal Vaccination

NCT00575653
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Not listed
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
11 Years to 21 Years
Enrollment
6,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
6
States / cities
Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 26, 2026, 2:52 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

NCT03037645
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma, Waldenstrom Macroglobulinemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
SNS-062
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Orange, California • San Diego, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

NCT02161757
View directory record Official record
Conditions
Uncontrolled Asthma
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
103
States / cities
Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT00944905
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Interventions
MDX-1203
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

NCT00938405
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions
Colesevelam HCl, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional

Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

NCT00002094
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 26, 2026, 2:52 AM EDT
Not listed Not applicable Interventional

Improve Functional Health Status in Minority Women With HIV

NCT04315675
View directory record Official record
Conditions
HIV/AIDS
Interventions
Guided Imagery Intervention, Cognitive Power Intervention, Combined Guided Imagery and Cognitive Power Intervention
Behavioral
Lead sponsor
Seton Hall University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ublituximab, Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

NCT00073177
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
37
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00478075
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, immunologic technique, samarium Sm 153 lexidronam pentasodium
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

NCT03283566
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Dependent Diabetes
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Study of Vemurafenib, Carboplatin, and Paclitaxel

NCT01636622
View directory record Official record
Conditions
Advanced Cancers
Interventions
Vemurafenib, Carboplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional

Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV

NCT01570595
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Cessation, Tobacco Use Disorder, Tobacco Dependence, Tobacco-Use Disorder, Virus, Human Immunodeficiency
Interventions
Web-Based Tailored Smoking Cessation Intervention, Standard of Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Ingestion and Cycling Related Immunity and Inflammation

NCT05407701
View directory record Official record
Conditions
Inflammatory Response, Metabolic Disturbance, Immune Suppression
Interventions
Cranberry Juice, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 26, 2026, 2:52 AM EDT
Completed No phase listed Observational

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156
View directory record Official record
Conditions
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

NCT00000866
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1, TBC-3B Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease

NCT01798966
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 26, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease

NCT00871702
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hodgkin Disease, Myelodysplastic Syndromes, Multiple Myeloma
Interventions
CD34-TK75 transduced donor lymphocytes, Sub Study - 18 FHBG PET/CT Scans
Genetic · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 26, 2026, 2:52 AM EDT